Everything below concerns Pro-Gly-Pro. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
As late as the 1960s, the element was also referred to simply as emanation. The first synthesized compound of radon, radon fluoride, was obtained in 1962. Even today, the word radon may refer to either the element or its isotope 222Rn, with thoron remaining in use as a short name for 220Rn to stem this ambiguity. The name actinon for 219Rn is rarely encountered today, probably due to the short half-life of that isotope. The danger of high exposure to radon in mines, where exposures can reach 1,000,000 Bq/m3, has long been known. In 1530, Paracelsus described a wasting disease of miners, the mala metallorum, and Georg Agricola recommended ventilation in mines to avoid this mountain sickness (Bergsucht). In 1879, this condition was identified as lung cancer by Harting and Hesse in their investigation of miners from Schneeberg, Germany. The first major studies with radon and health occurred in the context of uranium mining in the Joachimsthal region of Bohemia. In the US, studies and mitigation only followed decades of health effects on uranium miners of the Southwestern US employed during the early Cold War; standards were not implemented until 1971. In the early 20th century in the US, gold contaminated with the radon daughter 210Pb entered the precious metal supply chain of that country's jewelry industry. Gold brachytherapy seeds that had held 222Rn were illicitly or unknowingly sold and melted down. The presence of radon in indoor air was documented as early as 1950.
=== Fabrication of pure biomass based membrane === A biomass-based membrane is a membrane made from organic materials such as plant fibers. These membranes are often used in water filtration and wastewater treatment applications. The fabrication of a pure biomass-based membrane is a complex process that involves a number of steps. The first step is to create a slurry of the organic materials. This slurry is then cast onto a substrate, such as a glass or metal plate. The cast is then dried, and the resulting membrane is then subjected to a number of treatments, such as chemical or heat treatments, to improve its properties. One of the challenges in the fabrication of biomass-based membranes is to create a membrane with the desired properties.
Susie Orbach (born 6 November 1946), psychotherapist, psychoanalyst, writer and social critic; daughter of Maurice Orbach, author of Fat is a Feminist Issue, married to author Jeanette Winterson. She is honoured in BBC'S 100 Women in 2013 and 2014. She was the therapist to Diana, Princess of Wales during the 1990s. Yotam Ottolenghi (born 14 December 1968), Israeli-British celebrity chef; journalist for The Guardian and Haaretz; author of several cookery books, including Ottolenghi: The Cookbook (2008), Plenty (2010), Jerusalem (2012). Moved to Europe after his service in Military Intelligence Directorate (Israel); in 2014, London Evening Standard remarked that Ottolenghi had "radically rewritten the way Londoners cook and eat"; in 2017 was guest judge on Masterchef Australia. Ilan Pappé, pro-Palestinian dissident Israeli-British scholar, writer and author of Ashkenazi origin, focusing on the history of Palestinian Nakba, intifada, insurgency, land ownership and rights and radical Anti-Zionism. Joseph Pardo (c. 1624 – 1677), hazzan and writer David Patrikarakos; journalist and war correspondent, author of War in 140 Characters: How Social Media Is Reshaping Conflict in the Twenty-First Century; wrote Nuclear Iran: Birth of An Atomic State which was named as a New York Times Editor's Choice and nominated for Total Politics Book Awards. Ruthie Pearlman, Orthodox Jewish Crime Writer and writer of Young Adult Fiction.
Sources: en.wikipedia.org
=== Faith and beliefs === When asked if he believed in God, Freeman said: "It's a hard question because as I said at the start, I think we invented God. So if I believe in God, and I do, it's because I think I'm God." He later said that his experience working on The Story of God with Morgan Freeman did not change his views on religion, further stating that he sees Zoroastrianism being a belief system, that, "is intrinsically me: 'Good thoughts, good words, good deeds' sums it up. How many of us that believe in that?".
== Training == In the beginning stages of working as a diener, there are training requirements. Formal training requirements for a diener includes manual handling, infection control, and safety procedures. The training has two parts: Taught Units and Workplace Competency. The first portion, Taught Units, consists of five sections.
=== CHIP, Medicaid, and Medicare Coverage === In April 2025, the Trump Administration declined to finalize a Biden Administration proposal that would have required Medicare, Medicaid, and the Children's Health Insurance Program (CHIP) to broadly cover GLP-1 drugs for weight loss. In November 2025, the Trump Administration announced TrumpRx to lower the price of GLP-1 drugs to $245 per month for people covered by Medicare. Coverage for people with obesity and at least one comorbidity (elevated LDL-cholesterol, high blood pressure and/or MASLD) may be implemented as early as April 2026. The cost will be significantly higher because most insurance companies do not cover it in their formulary. Before this change, most people covered by Medicaid and CHIP paid $3 a month, the same as for brand-name medications. Starting in July 2026, eligible Medicare beneficiaries will gain access to certain weight-loss medications for $50 a month through a temporary initiative called the Medicare GLP-1 Bridge program. This pilot is designed to create a more affordable pathway for people who need these treatments while broader, long-term coverage options are being finalized.
Bromazepam is a "classical" benzodiazepine; other classical benzodiazepines include: diazepam, clonazepam, oxazepam, lorazepam, nitrazepam, flurazepam, and clorazepate. Its molecular structure is composed of a diazepine connected to a benzene ring and a pyridine ring, the benzene ring having a single nitrogen atom that replaces one of the carbon atoms in the ring structure. It is a 1,4-benzodiazepine, which means that the nitrogens on the seven-sided diazepine ring are in the 1 and 4 positions. Bromazepam binds to the GABAA receptor, causing a conformational change and increasing the inhibitory effects of GABA. It acts as a positive modulator, increasing the receptors' response when activated by GABA itself or an agonist (such as alcohol). As opposed to barbital, benzodiazepines are not GABA receptor activators and rely on increasing the neurotransmitter's natural activity. Bromazepam is an intermediate-acting benzodiazepine, is moderately lipophilic compared to other substances of its class and metabolised hepatically via oxidative pathways. It does not possess any antidepressant or antipsychotic qualities. After night time administration of bromazepam a highly significant reduction of gastric acid secretion occurs during sleep followed by a highly significant rebound in gastric acid production the following day. Bromazepam alters the electrical status of the brain causing an increase in beta activity and a decrease in alpha activity in EEG recordings.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.